RECRUITING

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific diagnosis or condition. This registry study will help the researchers learn more about the diagnosis, treatment, and quality of life of people with NF1-associated glioma. The researchers want to understand what happens as a result of different treatments for NF1-associated glioma and how these treatments and the disease itself affect people's lives over a period of time. Information collected during this study could affect how doctors diagnose, test, and treat NF1-associated glioma, and the study could help future patients with this type of cancer.

Official Title

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

Quick Facts

Study Start:2022-07-29
Study Completion:2025-07-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05489783

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Clinical diagnosis that meets NIH criteria for NF1 disease by either 1) documented clinical record establishing NF1 or 2) self-reported with supported documentation upon medical record collection.
  2. * Willing to have historical and future NF1 related health records sent to registry for review.
  3. * Radiologic or pathologically confirmed glioma.
  4. * Individuals ≥18 years of age on the date of informed consent.
  1. * Unwillingness to sign informed consent.
  2. * No proficiency in English or Spanish as determined by the Investigator.

Contacts and Locations

Study Contact

Anna Piotrowski, MD
CONTACT
212-610-0483
piotrowa@mskcc.org
Ingo Mellinghoff, MD
CONTACT
646-888-3036

Principal Investigator

Anna Piotrowski
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, 07645
United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, 11725
United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
Rockville Centre, New York, 11570
United States
Memorial Sloan Kettering West Harrison (All Protocol Activities)
West Harrison, New York, 10604
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Anna Piotrowski, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-29
Study Completion Date2025-07-29

Study Record Updates

Study Start Date2022-07-29
Study Completion Date2025-07-29

Terms related to this study

Keywords Provided by Researchers

  • NF1-associated glioma
  • Neurofibromatosis
  • Registry
  • 22-199

Additional Relevant MeSH Terms

  • Glioma